This "article" is ridiculous. It just throws financial metrics into a boilerplate and is likely automated to a large extent.
It's similar to ESPNs fantasy football "match up comparisons" from week to week where the computer just plugs in info and spits out a short comparison based on your line up projections.
I doubt anyone thinks someone is actually writing that for every single fantasy participant. This is no different IMO.
We all know that you can't base a buy/sell rating on a developmental biotech based in earnings or revenue. So this kind of "analysis" shouldn't fool anyone.
This was just a way to throw INO into a negative headline so the shorts can pile on.
News 
Market Data 
Discover 
